Request for Proposals

Melanoma Research Funding OpportunityClick here to receive future RFPs

MRA/ACS Joint Funding Opportunity: Understanding and Managing Metastasis 

The Melanoma Research Alliance (MRA) is pleased to announce a special funding opportunity jointly supported by MRA and the American Cancer Society (ACS), Understanding and Managing Metastasis in Melanoma and Other Cancers. 

MRA and ACS have each committed $1 million for the grant awards. The combined $2 million will be used to fund two team awards with terms of up to 3 years, at $1 million each. Proposals must include at least a 50% focus on melanoma research but need not be limited to this disease area. 

A request for applications (RFA) is now available to researchers at academic institutions in the United States. More information about the RFA and relevant deadlines can be found here

Please note the following key deadlines: 

  • January 16, 2019: Letters of Intent due
  • April 15, 2019: Full application due.
  • January 1, 2020: Grant term begins.

All proposals are due by 5:00 pm Eastern Time. Proposals should be submitted via the proposalCENTRAL on-line application tool: We strongly encourage you to share this RFP with your colleagues who might want to apply for funding. Please also inform us of others who might not be on our email list who should receive this announcement.

MRA 2018-2019 Request for Proposals

The Melanoma Research Alliance (MRA) announces a Request for Proposals (RFP) soliciting high-impact pre-clinical, translational, and early clinical research from scientists and clinicians around the world. The RFP calls for ideas that have the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment.

Proposals will be accepted for Established Investigator Awards, Pilot Awards, and Young Investigator Awards. Please note that the following Special Opportunities are available: 

  • Special Opportunity MRA Young Investigator and MRA Established Investigator Awards for Artificial Intelligence Applied to Melanoma
  • Special Opportunity MRA Young Investigator Award and Established Investigator Award in Dermatology
  • Special Opportunity Young Investigator Awards in Immunotherapy
  • Special Opportunity ASTRO-MRA Early Career Investigator Award in Radiation Oncology
  • Special Opportunity SITC-MRA Young Investigator Award in Immune-Related Adverse Events Associated with Immunotherapy

November 2, 2018: Deadline for all Established Investigator, Pilot, and Young Investigator Award full proposal applications.

November 9, 2018: Deadline for ASTRO-MRA Early Career Investigator full proposal applications.

Full descriptions of each award opportunity offered, including all Special Opportunity Awards, as well as eligibility criteria and instructions can be found in the MRA 2018-2019 RFP document:

MRA Second Release 2018-2019 Request for Proposals

MRA Award Terms and Conditions 


Tasheema Prince, MRA Scientific Program Manager

About Melanoma

Melanoma is a leading cause of new cancers, and more effective options for patients and those at risk are urgently needed. Recent scientific and clinical advances have provided new hope, but much work remains to be done to end suffering and death from melanoma.